JPWO2023044398A5 - - Google Patents

Info

Publication number
JPWO2023044398A5
JPWO2023044398A5 JP2024517157A JP2024517157A JPWO2023044398A5 JP WO2023044398 A5 JPWO2023044398 A5 JP WO2023044398A5 JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024517157 A JP2024517157 A JP 2024517157A JP WO2023044398 A5 JPWO2023044398 A5 JP WO2023044398A5
Authority
JP
Japan
Prior art keywords
subject
composition
use according
effective amount
administration provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534488A5 (https=
JP2024534488A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076516 external-priority patent/WO2023044398A1/en
Publication of JP2024534488A publication Critical patent/JP2024534488A/ja
Publication of JPWO2023044398A5 publication Critical patent/JPWO2023044398A5/ja
Publication of JP2024534488A5 publication Critical patent/JP2024534488A5/ja
Pending legal-status Critical Current

Links

JP2024517157A 2021-09-16 2022-09-15 ジストロフィノパチーを処置するための筋標的化複合体の投与 Pending JP2024534488A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163245162P 2021-09-16 2021-09-16
US63/245,162 2021-09-16
US202163250177P 2021-09-29 2021-09-29
US63/250,177 2021-09-29
US202163293619P 2021-12-23 2021-12-23
US63/293,619 2021-12-23
US202263348876P 2022-06-03 2022-06-03
US63/348,876 2022-06-03
PCT/US2022/076516 WO2023044398A1 (en) 2021-09-16 2022-09-15 Dosing of muscle targeting complexes for treating dystrophinopathies

Publications (3)

Publication Number Publication Date
JP2024534488A JP2024534488A (ja) 2024-09-20
JPWO2023044398A5 true JPWO2023044398A5 (https=) 2025-09-25
JP2024534488A5 JP2024534488A5 (https=) 2025-09-25

Family

ID=85603633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517157A Pending JP2024534488A (ja) 2021-09-16 2022-09-15 ジストロフィノパチーを処置するための筋標的化複合体の投与

Country Status (9)

Country Link
US (1) US20250018050A1 (https=)
EP (1) EP4401777A4 (https=)
JP (1) JP2024534488A (https=)
KR (1) KR20240058160A (https=)
AU (1) AU2022345986A1 (https=)
CA (1) CA3230451A1 (https=)
IL (1) IL311507A (https=)
MX (1) MX2024003373A (https=)
WO (1) WO2023044398A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025255283A1 (en) * 2024-06-07 2025-12-11 Dyne Therapeutics, Inc. Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906812A1 (en) * 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
WO2017192679A1 (en) * 2016-05-04 2017-11-09 Wave Life Sciences Ltd. Methods and compositions of biologically active agents
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
EP3829595A4 (en) * 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
JP7780691B2 (ja) * 2020-01-10 2025-12-05 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
AU2021206234A1 (en) * 2020-01-10 2022-09-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Similar Documents

Publication Publication Date Title
IL311507A (en) Dosing of muscle targeting complexes for the treatment of dystrophinopathy
IL309936A (en) Muscle targeting complexes and formulations for the treatment of dystrophinopathy
IL316206A (en) Dosage of muscle targeting complexes for the treatment of myotonic dystrophy
JPWO2023044398A5 (https=)
JP2024160045A5 (https=)
US20200277365A1 (en) Antagonist antibodies against gdf-8 and uses therefor
CN111527207B (zh) GalNAc衍生物
JP2026503873A (ja) Dmd遺伝子のエクソン45をスキップするための筋肉標的化複合体およびその使用
JP2023061927A5 (https=)
JP2021532831A5 (https=)
JPWO2021142307A5 (https=)
AU2021383343A1 (en) Anti-cd73 antibody, antibody-drug conjugate, and use thereof
JP2018530560A5 (https=)
JP2025512469A (ja) 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
JPWO2020028832A5 (https=)
JP2020509027A5 (https=)
JPWO2022020107A5 (https=)
JPWO2022026152A5 (https=)
JPWO2021154476A5 (https=)
JPWO2023283615A5 (https=)
JPWO2022147209A5 (https=)
JPWO2023201332A5 (https=)
JPWO2023283613A5 (https=)
JPWO2022271543A5 (https=)
JPWO2023283614A5 (https=)